Lightlake Therapeutics has announced that it filed an investigational new drug application for its intranasal naloxone therapy for the reversal of opioid overdose. The company also said that it has received additional funding from the National Institute on Drug Abuse (NIDA) for a new clinical trial of the product. Lightlake recently said that it had signed a … [Read more...] about Lightlake files IND for intranasal naloxone, gets additional NIDA funding
Business
ProStrakan to acquire Archimedes Pharma, PecFent nasal spray
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has announced that it will acquire PecFent fentanyl nasal spray manufacturer Archimedes Pharma for £230 million in cash. Archimedes, which is based in Reading, UK, received European marketing approval for PecFent in 2011. Archimedes sold its US business and the US version of PecFent, marketed as Lazanda, to Depomed in … [Read more...] about ProStrakan to acquire Archimedes Pharma, PecFent nasal spray
Merck sues Teva over mometasone furoate nasal spray
Following the submission by Teva of an ANDA for a generic mometasone furoate nasal spray, Merck has filed suit in the US District Court alleging infringement of US patent 6,127,353. The patent is due to expire in October 2017. In June 2012, a US District Court judge upheld the validity of the patent in a suit by Merck against Apotex but ruled that Merck had … [Read more...] about Merck sues Teva over mometasone furoate nasal spray
Biotie returns intranasal diazepam rights to Neurelis
Biotie Therapeutics has decided not to exercise its option to purchase Neurelis and is returning the rights to Neurelis's lead product, NRL-1 intranasal diazepam for the treatment of epileptic seizures. Biotie paid $1 million for the option to purchase Neurelis in June 2013. Under the deal, Biotie will still participate in any future revenues from the product to … [Read more...] about Biotie returns intranasal diazepam rights to Neurelis
Aegis gets patent for stable insulin for intranasal delivery, announces intranasal octreotide license availability
The US Patent and Trade Office (USPTO) has awarded Aegis Therapeutics US Patent No. 8,772,231 for "dramatically stabilized insulin formulations suitable for metered nasal spray delivery or injection based upon Aegis’ patented Intravail transmucosal absorption enhancer and ProTek protein stabilization technologies," the company said. According to Aegis, the company … [Read more...] about Aegis gets patent for stable insulin for intranasal delivery, announces intranasal octreotide license availability
Lightlake signs manufacturing contract for its intranasal naloxone
According to Lightlake Therapeutics, the company has signed a contract with a manufacturer for commercial production of its intranasal naloxone for the reversal of opioid overdose. In December 2013, the company announced positive initial results from a PK study of the product and said that it planned to submit an NDA in 2014. Lightlake CEO Roger Crystal commented, … [Read more...] about Lightlake signs manufacturing contract for its intranasal naloxone
Otsuka launches Meptin Swinghaler DPI in Japan
Otsuka has announced the launch of its new Meptin Swinghaler procaterol hydrochloride DPI for the treatment of asthma and COPD in Japan as of July 2, 2014. The Meptin Swinghaler was approved in Japan in February 2014. According to the company, Japan has over 1 million asthma patients, and Meptin's share of the Japanese market is over 50%. The Swinghaler, … [Read more...] about Otsuka launches Meptin Swinghaler DPI in Japan
Vectura announces new partnership for generic fluticasone propionate DPI
Vectura has announced a new US partnership for its VR506, which it describes as "an ICS for the treatment of asthma" and as "clinical stage asthma monotherapy delivered using Vectura’s proprietary technology." Elsewhere, the company has identified the product as a fluticasone propionate DPI. According to Vectura, it has signed the new agreement for development … [Read more...] about Vectura announces new partnership for generic fluticasone propionate DPI
Respiratory Technology Group at WIMR gets grant for development of inhaled vaccines
The Australian Research Council (ARC) has awarded a 3-year, $482,738 linkage grant titled "One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung" to members of the Respiratory Technology team at the Woolcock Institute of Medical Research (WIMR) and Evonik Industries. The partnership aims to develop a new, low-cost technology … [Read more...] about Respiratory Technology Group at WIMR gets grant for development of inhaled vaccines
Verona Pharma halts development of inhaled antitussive
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial. The trial evaluated the efficacy of a single dose of VRP700 in 20 idiopathic pulmonary fibrosis patients with severe chronic cough. … [Read more...] about Verona Pharma halts development of inhaled antitussive